Oncosoft (CEO Jin-sung Kim), a specialized company in AI-based radiotherapy solutions, has embarked on expanding its global market reach through the 'AAPM 2025' (American Association of Physicists in Medicine) held in the United States.
At this year's AAPM, the company showcased "OncoStudio," an AI-based automated contouring solution, and "OncoFlow," a radiotherapy workflow management platform. According to the company, the recently released OncoStudio 2.0 drew significant attention due to its substantial improvements in both speed and accuracy.
An official from Oncosoft stated, "More than half of the visitors were affiliated with university hospitals and medical schools, showing broad interest in both clinical and research fields. We confirmed our potential for global growth as visitors from 18 countries, including the U.S., Japan, and China, continued to visit our booth."
OncoStudio is AI software that automatically distinguishes between tumors and normal tissues in medical images such as CT and MRI scans. It can reduce tasks that previously took several hours to just a few minutes. OncoFlow is a platform that integrates and manages the entire radiotherapy process, allowing for systematic management of every stage from treatment planning to execution. According to the company, 30 medical institutions that visited the booth applied for demo services, showing particular interest in the modular functions and peer-review features.
An Oncosoft official added, "We are achieving concrete results through a systematic global entry strategy. Earlier this year, we obtained U.S. FDA clearance and achieved our first sales by supplying products to the Mayo Clinic. We are currently targeting the North American market through our local U.S. subsidiary. Furthermore, following the acquisition of medical device certification in Japan, we are preparing to enter the European and Southeast Asian markets."
Oncosoft also conducted oral presentations at this AAPM. Joo-young Son, Head of the U.S. subsidiary, emphasized the necessity of a vendor-neutral platform under the theme of OncoFlow. CTO Han-ju Chae introduced the achievements of OncoStudio, which reached over 90% accuracy with ultra-fast inference in less than one minute.
The company plans to unveil an 'Interactive AI Agent' feature at the American Society for Radiation Oncology (ASTRO) meeting in September. This feature will assist medical staff in performing treatment planning tasks by communicating with the AI through chat or voice commands.
Jin-sung Kim, CEO of Oncosoft, said, "Through this AAPM, we have confirmed our global growth potential by having our technological prowess recognized by international medical professionals. Moving beyond simple automation, we will present a new standard for radiotherapy by implementing a true 'AI Primary Care Physician' that assists medical staff in decision-making."
